Loading company…
Semnur Pharmaceuticals develops non-opioid treatments for chronic pain, including lumbar radicular pain and sciatica.
Founded in 2013 in Los Altos, US, Semnur Pharmaceuticals, Inc. develops non-opioid therapies for chronic pain. Its lead product, SP-102 (SEMDEXA™), is a preservative-free injectable corticosteroid gel for moderate to severe chronic radicular pain, used in transforaminal injections. Scintilla Pharmaceuticals, Inc. acquired the company in August 2016 for an initial USD 60 mn plus performance-based payments, and its CEO is Jaisim S. The company sells to hospitals and pain management clinics on a B2B basis.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in